Jan Schrooten
CEO
Antleron
Antleron develops personalized therapies, tissues, and organs by integrating cell engineering, biomaterials, and bioprocessing technologies. The company addresses the need for scalable and affordable regenerative medicine solutions, enabling faster transitions from laboratory innovations to patient applications.
- Biotechnology
Updated 6 months ago
Funding
Funding rounds are not available yet.
Founders
Product
Problem
The development of personalized therapies, tissues, and organs faces challenges in scalability, manufacturability, and affordability, hindering the transition of regenerative medicine innovations from the lab to patient applications. Current methods often struggle to produce therapies at the scale and cost required for widespread clinical use.
Solution
Antleron aims to accelerate the development and manufacturing of personalized therapies by integrating cell engineering, biomaterials, and bioprocessing technologies. Their "Cell by Design®" approach provides biomedical and biotechnology organizations with robust concept data to drive scalability and manufacturability. By co-creating end-to-end solutions, Antleron seeks to transform healthcare by enabling the engineering of innovative bioprocesses for advanced therapies.
Target Audience
Antleron's primary customers are biomedical and biotechnology organizations involved in the development of regenerative medicine and advanced personalized therapies.
Features
- Cell by Design®: A methodology for optimizing and controlling the cell therapy development process.
- Multidisciplinary specialists providing expertise in cell engineering, biomaterials, and bioprocessing.
- End-to-end solutions for engineering innovative bioprocesses.
- Focus on scalability, manufacturability, and affordability of personalized therapies.